Saipem wins USD121 million in drilling contracts

27. Oct 2026

(AWP Alliance News) - The following is a round-up of updates by global companies, issued on Saturday, Sunday and Monday, and not separately reported by Alliance News:

----------

Saipem Spa - Milan, Italy-based engineering and oilfield services company - Receives two offshore drilling contracts worth a total value of approximately USD121 million. The first contract, with Eni Cyprus Ltd, covers offshore drilling activities within the exclusive economic zone of Cyprus using the drillship Saipem 10000, with operations expected to begin between November 2026 and January 2027. The second contract, with Eni Ghana Exploration & Production Ltd, involves the use of the semi-submersible rig Scarabeo 9 for drilling activities offshore Ghana.

----------

Meta Platforms Inc - Menlo Park, California-based owner of Facebook, Instagram and WhatsApp and Nvidia Corp - Santa Clara, California-based chipmaker - Expand their partnership on Muse and the Muse family of models. Meta says the partnership will "improve inference and training performance, reflecting popular demand for useful AI agents." Meta intends to expand the deployment of Nvidia infrastructure, including Vera Rubin and Vera CPUs for next-generation AI agents to deliver maximum performance per watt. Meta will also deploy Nvidia Spectrum-X Ethernet networking and BlueField-4 to support network efficiency and throughput. Nvidia, for its part, will invest USD3.0 billion in Meta's equity offering. "Muse is how we bring personal superintelligence to everyone. We're excited to keep working with Nvidia to deliver the best personal agents and frontier models for billions of people," says Mark Zuckerberg, founder and chief executive of Meta.

----------

Pfizer Inc - New York-based drug developer - Notes results of the MagnetisMM-32 study evaluating its Elrexfio treatment. The study covers adults with relapsed or refractory multiple myeloma who received at least one prior line of treatment with anti-CD38 therapy and lenalidomide. Elrexfio demonstrated a statistically significant and clinically meaningful reduction in the risk of disease progression or death versus investigator's choice of elotuzumab, pomalidomide and dexamethasone; pomalidomide, bortezomib and dexamethasone; or carfilzomib and dexamethasone, according to Pfizer. Over 75% of patients receiving Elrexfio had not experienced disease progression or death from any cause at the time of the analysis, with an estimated 68% progression-free survival at 18 months. "MagnetisMM-32 demonstrates that Elrexfio...delivers a significant and clinically meaningful progression-free survival benefit and an encouraging safety profile in this increasingly important treatment setting, with median PFS not yet reached and a high percentage of patients remaining progression-free at the time of analysis," says Jeff Legos, chief oncology officer at Pfizer.

----------

TotalEnergies SE - Paris-based oil major - Subsidiary TotalEnergies EP Nigeria has completed its divestment of 10% non-operated interest in the Renaissance JV licenses to Vaaris Resources JVCo Ltd for a total amount of USD800 million.

----------

Amgen Inc - Thousand Oaks, California-based biotechnology company - To present new data across its portfolio at American College of Rheumatology Convergence 2026 in Orlando, Florida. The company will present Oasiz-301 study data on its Dazodalibep treatment for Sjogren's disease, demonstrating "statistically significant and clinically meaningful reductions in systemic disease activity compared with placebo," according to Amgen. Additional treatments include Uplizna in the treatment of IgG4, Tavneos in the treatment of ANCA-associated vasculitis and Krystexxa in the treatment of treatment of chronic gout.

----------

By John Robaina, Alliance News reporter

Comments and questions to newsroom [at] alliancenews.com